Proprietary kinase inhibitor drug discovery platform leveraging a chemical library of covalent kinase inhibitors, structure-based drug design, and custom kinase assays. Mechanisms include reversible/irreversible covalent inhibitors, molecular glues, tissue-specific inhibitors, and targeted protein degraders. Focus: chronic inflammation and autoimmune diseases.

Biotech Distilled coverage (4)

2026-05-08 UPDATE: Aclaris Therapeutics (ACRS) - The Quiet ATM 🔒 Paid
2026-04-29 UPDATE: Aclaris Therapeutics (ACRS) - The Bispecific Delivered 🔒 Paid
2026-03-28 UPDATE: Aclaris Therapeutics (ACRS) - Unpacking The Phase 2a Data for ATI-2138 🔒 Paid
2026-03-24 Aclaris Therapeutics (ACRS) - Scientific Deep Dive for Bosakitug, ATI-052, and Other Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.